Kyle Kingma 8/20/24 Kyle Kingma 8/20/24

EMulate Therapeutics Inc. Announces Publication of Pre-Clinical Mouse Model Demonstrating Direct Evidence of Immune Checkpoint Receptor Knock-Down in a Mouse Glioblastoma Model

Kyle Kingma 4/11/24 Kyle Kingma 4/11/24

EMulate Therapeutics Announces the Publication of the Evaluation of Its Ultra-Low Radiofrequency Energy Device in Murine Model of Glioblastoma in BMC Bioelectric Medicine

Kyle Kingma 11/15/23 Kyle Kingma 11/15/23

EMulate Therapeutics Inc. Announces Publication of Clinical Results at the SNO 2023 Conference: GBM and DIPG

Kyle Kingma 11/9/23 Kyle Kingma 11/9/23

Society for Neuro-Oncology Abstract

Kyle Kingma 7/18/23 Kyle Kingma 7/18/23

EMulate Therapeutics Announces the Publication of Its Phase I/II Results in CNS Oncology: “An Expanded Safety/Feasibility Study of the EMulate Therapeutics Voyager in Patients with Recurrent GBM”

EMulate Therapeutics Announces the Publication of Its Phase I/II Results in CNS Oncology: “An Expanded Safety/Feasibility Study of the EMulate Therapeutics Voyager™ System in Patients with Recurrent Glioblastoma”

Kyle Kingma 7/18/23 Kyle Kingma 7/18/23

EMulate Therapeutics Announces Brett Greene, Veteran in the Psychedelic and Cannabinoid Biotechnology Industry, as a Company Advisor

Kyle Kingma 11/22/22 Kyle Kingma 11/22/22

Magnetic field tech captures the ‘song’ of a drug

Kyle Kingma 10/18/22 Kyle Kingma 10/18/22

EMulate Therapeutics Announces the Publication of Positive Pre-clinical Data Evaluating Pain Reduction via Delivery of Low and Ultra-low Radio Frequency Energy

Kyle Kingma 6/7/22 Kyle Kingma 6/7/22

EMulate Therapeutics Announces the Incorporation of A New Wholly Owned Subsidiary

Kyle Kingma 5/10/22 Kyle Kingma 5/10/22

EMulate Therapeutics Announces Promotion of Kyle Kingma to SVP, Finance, and GM, EMulate Subsidiaries - Corporate Update Announcement

Kyle Kingma 3/29/22 Kyle Kingma 3/29/22

The Age of Digital Therapeutics is Upon Us: EMulate Therapeutics, Inc.

It all begins with an idea.

Kyle Kingma 3/7/22 Kyle Kingma 3/7/22

EMulate Therapeutics Announces Issuance Of 41st Patent Covering The Design Of A Pediatric Therapeutic Device For Cancer And Other Health Indications

Kyle Kingma 2/23/22 Kyle Kingma 2/23/22

EMulate Therapeutics Announces the Incorporation of a Third Wholly Owned Subsidiary

Kyle Kingma 2/15/22 Kyle Kingma 2/15/22

EMulate Therapeutics Issues White Paper Detailing Magnetic Field Effects Via Low and Ultra-Low Radio Frequency Energy (ulRFE(R))

Kyle Kingma 2/1/22 Kyle Kingma 2/1/22

EMulate Therapeutics 2021 Year in Review - A Pivotal Year for the Company

Kyle Kingma 11/17/21 Kyle Kingma 11/17/21

EMulate Therapeutics Announces the Incorporation of Two Wholly Owned Subsidiaries

Kyle Kingma 9/28/21 Kyle Kingma 9/28/21

EMulate Therapeutics Announces Issuance of Additional U.S. Patent Covering a Therapeutic Device for Cancer and Other Health Indications